目的:自我报告的与疼痛相关的心理变量被认为是纤维肌痛(FM)女性生活质量的主要因素,在该人群中实施治疗策略时应予以考虑。这项研究的目的是探讨低压高压氧治疗(HBOT)对与疼痛相关的心理结构的影响(即,痛苦灾难论,痛苦的接受,疼痛缺乏灵活性,精神上的失败)和FM女性的生活质量。
方法:这是一项随机对照试验。33名FM患者被随机分配到低压高压氧治疗组(HBOTG)(n=17),谁接受了为期8周的干预(每周5次),和对照组(CG)(n=16)。在基线(T0)和完成研究(T1)时评估所有女性的自我感知疼痛强度,痛苦灾难论,痛苦的接受,疼痛缺乏灵活性,精神上的失败和生活质量。
结果:在T1时,HBOTG在与疼痛相关的所有变量中都得到了改善(即自我感知的疼痛强度,痛苦灾难论,痛苦的接受,疼痛的灵活性,精神失败)(p<0.05)和生活质量(p<0.05)。相比之下,CG在任何变量方面均无改善.此外,干预后两组生活质量差异有统计学意义(p<0.05)。
结论:HBOT可有效改善与疼痛相关的心理结构(即疼痛灾难,痛苦的接受,疼痛的灵活性,精神上的失败)和FM女性的生活质量。临床试验链接临床试验gov标识符(NCT03801109)。
Self-reported psychological variables related to pain have been posited as the major contributors to the quality of life of fibromyalgia (FM) women and should be considered when implementing therapeutic strategies among this population. The aim of this
study was to explore the effect of low-pressure hyperbaric oxygen therapy (HBOT) on psychological constructs related to pain (i.e., pain catastrophism, pain acceptance, pain inflexibility, mental defeat) and quality of life in women with FM.
This was a randomized controlled
trial. Thirty-three women with FM were randomly allocated to a low-pressure hyperbaric oxygen therapy group (HBOTG) (n=17), who received an 8-week intervention (5 sessions per week), and a control group (CG) (n=16). All women were assessed at baseline (T0) and upon completion of the
study (T1) for self-perceived pain intensity, pain catastrophism, pain acceptance, pain inflexibility, mental defeat and quality of life.
At T1, the HBOTG improved across all variables related to pain (i.e. self-perceived pain intensity, pain catastrophism, pain acceptance, pain flexibility, mental defeat) (p<0.05) and quality of life (p<0.05). In contrast, the CG showed no improvements in any variable. Furthermore, significant differences between the groups were found in quality of life (p<0.05) after the intervention.
HBOT is effective at improving the psychological constructs related to pain (i.e. pain catastrophism, pain acceptance, pain flexibility, mental defeat) and quality of life among women with FM. Clinical
Trial Link Clinical Trials gov identifier (NCT03801109).